Efficacy of c-Met inhibitor for advanced prostate cancer

Efficacy of c-Met inhibitor for advanced prostate cancer

<p>Abstract</p> <p>Background</p> <p>Aberrant expression of HGF/SF and its receptor, c-Met, often correlates with advanced prostate cancer. Our previous study showed that expression of c-Met in prostate cancer cells was increased after attenuation of androgen receptor (...

Full description

Bibliographic Details
Main Authors:	Christensen James G, Clark Curtis, Zhu Chunfang, Tu William H, Sun Zijie
Format:	Article
Language:	English
Published:	BMC 2010-10-01
Series:	BMC Cancer
Online Access:	http://www.biomedcentral.com/1471-2407/10/556

Similar Items

Targeting c-MET to Enhance the Efficacy of Olaparib in Prostate Cancer
by: Wang Z, et al.
Published: (2021-08-01)

HGF/c-Met Axis: The Advanced Development in Digestive System Cancer
by: Zhiwei Shao, et al.
Published: (2020-10-01)

Development of antibody-based c-Met inhibitors for targeted cancer therapy
by: Lee D, et al.
Published: (2015-02-01)

The Role of MET Inhibitor Therapies in the Treatment of Advanced Non-Small Cell Lung Cancer
by: Ramon Andrade De Mello, et al.
Published: (2020-06-01)

An Orally Available Small-Molecule Inhibitor of c-Met, PF-2341066, Reduces Tumor Burden and Metastasis in a Preclinical Model of Ovarian Cancer Metastasis
by: Marion Zillhardt, et al.
Published: (2010-01-01)

A phase II study of the efficacy and safety of the MET inhibitor capmatinib (INC280) in patients with advanced hepatocellular carcinoma
by: Shukui Qin, et al.
Published: (2019-12-01)

PHA665752, a small-molecule inhibitor of c-Met, inhibits hepatocyte growth factor-stimulated migration and proliferation of c-Met-positive neuroblastoma cells
by: Durden Donald L, et al.
Published: (2009-11-01)

Efficacy and safety of photoselective vaporization of the prostate in patients with prostatic obstruction induced by advanced prostate cancer
by: Yuan-Tso Cheng, et al.
Published: (2011-07-01)

Activation of c-MET induces a stem-like phenotype in human prostate cancer.
by: Geert J L H van Leenders, et al.
Published: (2011-01-01)

ADAM15/PTK6/cMET interplay : promotors of prostate cancer progression
by: Hurtz, Melanie
Published: (2017)

Cost-efficacy analysis of hormonal treatments for advanced prostate cancer
by: Sergio Iannazzo, et al.
Published: (2008-09-01)

Evodiamine Mitigates Cellular Growth and Promotes Apoptosis by Targeting the c-Met Pathway in Prostate Cancer Cells
by: Sun Tae Hwang, et al.
Published: (2020-03-01)

Multiplexed quantum dot labeling of activated c-Met signaling in castration-resistant human prostate cancer.
by: Peizhen Hu, et al.
Published: (2011-01-01)

(−)-Oleocanthal as a Dual c-MET-COX2 Inhibitor for the Control of Lung Cancer
by: Abu Bakar Siddique, et al.
Published: (2020-06-01)

MET Gene Amplification and MET Receptor Activation Are Not Sufficient to Predict Efficacy of Combined MET and EGFR Inhibitors in EGFR TKI-Resistant NSCLC Cells.
by: Dario Presutti, et al.
Published: (2015-01-01)

The Significance of MET Expression and Strategies of Targeting MET Treatment in Advanced Gastric Cancer
by: Haiyan Liao, et al.
Published: (2021-09-01)

Prognosis and Concurrent Genomic Alterations in Patients With Advanced NSCLC Harboring MET Amplification or MET Exon 14 Skipping Mutation Treated With MET Inhibitor: A Retrospective Study
by: Li Liu, et al.
Published: (2021-06-01)

Clinical significance of c-Met and phospho-c-Met (Tyr1234/1235) in ovarian cancer
by: Ling Lim, et al.
Published: (2019-01-01)

Erratum to A phase II study of the efficacy and safety of the MET inhibitor capmatinib (INC280) in patients with advanced hepatocellular carcinoma
Published: (2020-03-01)

Therapeutic Efficacy of ABN401, a Highly Potent and Selective MET Inhibitor, Based on Diagnostic Biomarker Test in <i>MET</i>-Addicted Cancer
by: Jooseok Kim, et al.
Published: (2020-06-01)

Conditional deletion of the Pten gene in the mouse prostate induces prostatic intraepithelial neoplasms at early ages but a slow progression to prostate tumors.
by: Mi Kyung Kwak, et al.
Published: (2013-01-01)

MET inhibitors for targeted therapy of EGFR TKI-resistant lung cancer
by: Qiming Wang, et al.
Published: (2019-06-01)

Tumor and Plasma Met Levels in Non-Metastatic Prostate Cancer.
by: Deborah R Kaye, et al.
Published: (2016-01-01)

Advances in Prognostic Methylation Biomarkers for Prostate Cancer
by: Dilys Lam, et al.
Published: (2020-10-01)

Discovery of novel androgen receptor inhibitors as prospective therapeutics for advanced prostate cancer
by: Li, Huifang
Published: (2015)

The Role of PARP Inhibitors in the Treatment of Prostate Cancer: Recent Advances in Clinical Trials
by: Mingyue Xia, et al.
Published: (2021-05-01)

Enhancing the Radiation Response in KRAS Mutant Colorectal Cancers Using the c-Met Inhibitor Crizotinib
by: Kyle C. Cuneo, et al.
Published: (2019-02-01)

Research Progress of HGF/c-MET Inhibitor in the Treatment  of Non-small Cell Lung Cancer
by: Tao JIANG, et al.
Published: (2015-04-01)

Development of bispecific anti-c-Met/PD-1 diabodies for the treatment of solid tumors and the effect of c-Met binding affinity on efficacy
by: Qingyun Yuan, et al.
Published: (2021-01-01)

Crizotinib in advanced non-small-cell lung cancer with concomitant ALK rearrangement and c-Met overexpression
by: Rui-Lian Chen, et al.
Published: (2018-11-01)

New Preclinical Development of a c-Met Inhibitor and Its Combined Anti-Tumor Effect in c-Met-Amplified NSCLC
by: Nam Ah Kim, et al.
Published: (2020-02-01)

Advances in Prostate Cancer
Published: (2013)

c-Met and miRs in Cancer
by: Simona Giglio, et al.
Published: (2015-01-01)

MET Inhibitors for the Treatment of Gastric Cancer: What’s Their Potential?
by: El Darsa H, et al.
Published: (2020-10-01)

Integrin Inhibitors in Prostate Cancer
by: Maylein C. Juan-Rivera, et al.
Published: (2018-02-01)

EVALUATION OF EFFICACY OF BUSERELIN-DEPO IN PATIENTS WITH LOCALLY ADVANCED AND METHASTATIC PROSTATE CANCER
by: S. V. MISHUGIN, et al.
Published: (2017-06-01)

Role of the HGF/c-MET tyrosine kinase inhibitors in metastasic melanoma
by: Lucia Demkova, et al.
Published: (2018-02-01)

The c-Met Inhibitor MSC2156119J Effectively Inhibits Tumor Growth in Liver Cancer Models
by: Friedhelm Bladt, et al.
Published: (2014-08-01)

c-MET Pathway and its Inhibitors in Non-Small Cell Lung Cancer: Current Situation and Challenges
by: Fei YAN, et al.
Published: (2017-09-01)

MET transcriptional regulator/serine peptidase inhibitor kunitz type 1 panel operating through HGF/c‐MET axis as a prognostic signature in pan‐cancer
by: Yi Xiang, et al.
Published: (2021-04-01)